Continuing Medical Education
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 14.25 of AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Who Should Attend
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists, and other healthcare providers involved and/or interested in the diagnosis, treatment, and management of patients with breast cancer.
Objectives
After successful completion of this course, attendees should be able to:
- Discuss cancer issues in women, focusing on gynecological malignancies and problems unique to women with lung cancer
- Evaluate genomic and proteomic tools for the assessment of recurrence risk, prediction of benefit from chemotherapy, and individualization of therapeutic decision making, while identifying the latest and most important prognostic and predictive factors in breast cancer
- Discuss recent advancements in surgery and radiation therapy for the treatment of breast cancer
- Review emerging research findings concerning breast cancer risk and chemoprevention
- Comment on the latest translational research developments improving our understanding of breast tumor biology and subsequent therapeutic choices
- Summarize current therapeutic options for the management of patients with early-stage or locally advanced breast cancer
- Compare and contrast the most appropriate treatment regimens utilizing neoadjuvant and adjuvant therapies
- Review current and emerging research in the pathogenesis and therapies for triple-negative breast cancers
- Describe the biologic rationale for HER2-targeted therapies, and discuss recent clinical trial data evaluating novel HER2-directed agents in early-stage and advanced disease
- Compare endocrine treatment options, including timing and sequencing of aromatase inhibitors in adjuvant regimens and the integration of bisphosphonates, for patients with hormone receptor-positive breast cancer
- List the most promising current and future strategies for the management of metastatic breast cancer
- Interpret and integrate recent clinical trial data into improved patient management strategies
Deborah K. Armstrong, MD
Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine
Baltimore, Maryland
Susana Campos, MD, MPh
Dana Farber Cancer Institute
Boston, Massachusetts
Scott Christensen, MD
University of California, Davis
Davis, California
Mary Cianfrocca, DO
Northwestern University School of Medicine
Chicago, Illinois
Maura N. Dickler, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Stefan Glück, MD
University of Miami
Miller School of Medicine
Miami, Florida
Harold Harvey, MD
Pennsylvania State University
Hershey Medical Center
Hershey, Pennsylvania
Mohammad Jahanzeb, MD, FACP
Aptium Oncology
Boca Raton, Florida
Virginia Kaklamani, MD, DSc
Northwestern University School of Medicine
Chicago, Illinois
Krystyna D. Kiel, MD
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
Savannah, Georgia
Monica Morrow, FACS
Memorial Sloan-Kettering Cancer Center
New York, New York
Ruth M. O’Regan, MD
Emory University Winship Cancer Institute
Atlanta, Georgia
Christy A. Russell, MD
University of Southern California
Los Angeles, California
Stephen F. Sener, MD
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Vered Stearns, MD
Johns Hopkins School of Medicine Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Fraser Symmans, MD
University of Texas
MD Anderson Cancer Center
Houston, Texas
Victor G. Vogel, MD, MHS, FACP
University of Pittsburgh
Pittsburgh, Pennsylvania
Antoinette J. Wozniak, MD, FACP
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Antoinette J. Wozniak, MD, FACP
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Friday, August 21, 2009
Pre-conference: Women’s cancer issues
8:00 am
Welcome and introduction
8:05 am
Women and lung cancer
Antoinette J. Wozniak, MD, FACP
8:30 am
Ovarian cancer
Deborah K. Armstrong, MD
8:55 am
Pregnancy and cancer
Mary Cianfrocca, DO
9:20 am
Coffee break
9:40 am
Cervical cancer
Susana M. Campos, MD, MPH
10:05 am
Uterine cancer
Deborah K. Armstrong, MD
10:30 am
Panel discussion
10:45 am
CHALLENGING CASES I
This special session will consist of challenging clinical scenarios presented by the audience to a panel of medical oncologists, gynecologic oncologists, surgeons, and radiation oncologists. The interactive nature of this session will enhance the learning process and give attendees a unique opportunity to obtain feedback on difficult patient cases from a panel of experts in the fields of breast cancer and gynecologic oncology.
12:00 pm
Lunch break
General Sessions
1:00 pm
Welcome and introduction
Session I: Surgery/Radiotherapy
1:10 pm
Keynote lecture: Recent advances in the surgical management of breast cancer
Monica Morrow, FACS
1:55 pm
Patient selection for breast cancer surgery
Stephen F. Sener, MD
2:20 pm
Controversies and updates in radiation oncology
Krystyna D. Kiel, MD
2:45 pm
Panel discussion
3:00 pm
Coffee break
Session II: Translational research in advanced/metastatic disease
3:15 pm
The role of VEGF inhibitors in breast cancer
Maura N. Dickler, MD
3:40 pm
HER2-positive metastatic disease
and overcoming resistance to anti-HER2 therapy
Mohammad Jahanzeb, MD, FACP
4:05 pm
Therapeutic options for hormone refractory disease
Ruth M. O’Regan, MD
4:30 pm
Emerging data on the management of triple-negative breast cancer in the adjuvant and metastatic setting
Stefan Glück, MD
4:55 pm
Treatment of bone metastases in patients with advanced breast cancer
Harold Harvey, MD
5:20 pm
Panel discussion
5:30 pm
Adjourn
Saturday, August 22, 2009
8:00 am
Welcome to day two
Session III: Prevention, detection, and prognosis
8:10 am
BRCA1/BRCA2 in 2009: Clinical updates and ongoing research
Virginia Kaklamani, MD, DSc
8:35 am
The genetics and management of patients at high-risk for breast cancer
Virginia Kaklamani, MD, DSc
9:00 am
Chemoprevention for breast cancer: Where are we headed?
Victor G. Vogel, MD, MHS, FACP
9:25 am
What is the role of CYP2D6 in pre-menopausal women with ER+ breast cancer?
Vered Stearns, MD
9:50 am
Panel discussion
10:05 am
Coffee break
10:25 am
CHALLENGING CASES II
This special session will consist of challenging clinical scenarios presented by the audience to a panel of medical oncologists, gynecologic oncologists, surgeons, and radiation oncologists. The interactive nature of this session will enhance the learning process and give attendees a unique opportunity to obtain feedback on difficult patient cases from a panel of experts in the fields of breast cancer and gynecologic oncology.
12:00 pm
Lunch break
Session IV: Molecular profiling
1:00 pm
Keynote lecture: Overview of the role of molecular profiling in guiding therapeutic choices for breast cancer treatment
Fraser Symmans, MD
1:45 pm
Appropriate management of small cancers
Christy A. Russell, MD
2:10 pm
Is pCR important in ER+ cancers?
Ruth M. O’Regan, MD
2:35 pm
Panel discussion
2:50 pm
Coffee break
Session V: Adjuvant therapy
3:10 pm
Adjuvant therapy: How to make the right choice
Scott Christensen, MD
3:35 pm
What therapy should be given pre-operatively for HER2-positive breast cancers?
Mohammad Jahanzeb, MD, FACP
4:00 pm
The role of bisphosphonates in the adjuvant setting
Harold Harvey, MD
4:25 pm
Panel discussion
4:40 pm
Adjourn
Discounted $195.00
Payment received by June 18, 2009
Regular $295.00
Payment received by August 13, 2009
Full/Onsite: $395.00
Payment recieved after August 13, 2009
Physicians Group discount $-50.00
Must register at the same time; cannot be combined with any other discounts and have proof of eligibility with registration)
Nurses/Residents/Students
$75.00
Proof of eligibility must accompany registration
To Register: You may register online www.imedex.com, by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting. To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
The Registration and Information Desk at the Westin New York will be staffed:
Friday, August 21, 2009—7:00 am – 5:30 pm
Saturday, August 22, 2009—7:00 am – 4:40 pm
Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for Nurses/Residents/Student rates.
Payment: To pre-register, registration and payment must be received no later than August 13, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than August 13, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after August 13, 2009.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this conference should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
Conference Location and Hotel Accommodations
Westin New York at Times Square
270 West 43rd Street
New York, New York 10036
Tel.: +1 (212) 201 2700
Fax: +1 (212) 201 2701
http://www.starwoodmeeting.com/Book/imedex15thannualpers
The Westin New York at Times Square stands at the heart of a vivid action-packed metropolis. From thrilling sights to gourmet restaurants to Broadway’s glittering star-studded performances – New York delivers something unforgettable for everyone.
For the convenience of attendees, a limited number of rooms have been reserved until July 30, 2009 at a discounted rate of $239 single/double occupancy, plus tax, currently at 14.25% as well as $3.50 New York City Occupancy Tax. This rate is not guaranteed outside the conference dates or after July 30, 2009.
To reserve your room please contact the Westin New York at Times Square reservations department at +1 (212) 201 2700 or visit the hotel’s website at http://www.starwoodmeeting.com/Book/imedex15thannualpers. To receive the group rate, callers must identify themselves as being with the Perspectives in Breast Cancer group. Reservation requests received after July 30, 2009 may not be guaranteed the group rate.
Chairs:
Chairs: Ruth M. O'Regan, MD
Emory University Winship Cancer Institute
Atlanta, Georgia
Christy A. Russell, MD
University of Southern California
Los Angeles, California
Dear Colleague,
It is with great pleasure and enthusiasm that we invite you to attend the 15th Annual Perspectives in Breast Cancer. This year marks the 15th anniversary of Perspectives in Breast Cancer, which has become a dynamic forum for leaders in breast cancer research and patient care to increase their knowledge and share their challenges and successes in disease management. In addition, we have added a half-day seminar on the management of other women’s malignancies, including lung cancer, gynecologic cancers, and pregnancy and cancer.
Significant media and medical attention to breast cancer has stimulated research dedicated to the prevention, detection, diagnosis, and treatment of this disease. As a result, our knowledge of the etiology and mechanisms of the disease has unfolded at a highly accelerated pace. Many clinicians who treat women with breast cancer are also interested in the treatment of other malignancies unique to women, including adenocarcinoma of the lung, gynecologic malignancies, and the delivery of systemic therapy to women who are pregnant while being treated for cancer.
This conference is designed to provide you, as a practicing clinician, with a comprehensive overview of these important and evolving fields. Our panel, composed of leading clinicians and researchers in breast cancer, lung, and gynecologic malignancies, will provide the latest information on state-of-the-art developments from the leading cancer centers and academic institutions.
Please join us in New York for what promises to be a rewarding professional update.
Sincerely,
Ruth M. O’Regan, MD
Christy A. Russell, MD
ORGANIZER
Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2008 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
The following company has provided an educational grant in support of this conference:
PLATINUM
Genentech BioOncology
BRONZE
CORPORATE
Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.
The following company is an exhibitor at this conference:
Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712 or by email at c.gunter@imedex.com.
